Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Gene Ther. 2014 Apr 10;21(6):599–608. doi: 10.1038/gt.2014.33

Table 3.

Summary of LFB staining in brain, spinal cord, and ON and clinical symptoms in mice injected with PLP. a

Demyelination
Brain Spinal cord Optic Nerve Clinical symptom
Treatment % b Meanc ± SEM % b Meanc ± SEM % b Meanc ± SEM % Score Mortality
PLP 87 194±96 50 82±64 0 0 0 0 0
PLP+IFN-β DNA 33 5±2 0 0 0 0 0 0 0
PLP+HSV-IL-12p70 100 206±18 50 85±25 0 0 0 0 0
a

Mice were immunized with PLP peptide as we described in Materials and methods. Some of the MOG immunized mice were injected with IFN-β DNA, while some mice were ocularly infected with 2X107 PFU/eye of HSV-IL-12p70. The presence of demyelination in ONs, SCs, and brains was assessed on day 29 post treatment. Clinical symptomatology was assessed daily for 29 days or until death.

b

Percent of mice showing demyelination.

c

Area of plaque/section ± standard error of mean (SEM) in treated mice.